These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38131531)

  • 1. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
    Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
    Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
    Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
    Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
    Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
    Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction.
    Wang C; Xu Y; Lin Y; Zhou Y; Mao F; Zhang X; Shen S; Zhang Y; Sun Q
    Breast; 2022 Jun; 63():61-70. PubMed ID: 35334240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
    Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
    Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
    Richman J; Ring A; Dowsett M; Sestak I
    Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea.
    Lee JH; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Front Oncol; 2021; 11():691277. PubMed ID: 34239805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.
    Dejthevaporn T; Patanayindee P
    Breast Cancer (Auckl); 2023; 17():11782234231186869. PubMed ID: 37533837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value.
    Wang C; Chen C; Lin Y; Zhou Y; Mao F; Zhu H; Zhang X; Shen S; Huang X; Wang X; Zhao B; Yang J; Sun Q
    Sci Rep; 2020 Mar; 10(1):4660. PubMed ID: 32170181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
    Villasco A; Accomasso F; D'Alonzo M; Agnelli F; Sismondi P; Biglia N
    Breast Cancer; 2021 Sep; 28(5):1131-1140. PubMed ID: 33939116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.
    Chumsri S; Pai T; Ma Y; Li Z; Gil A; Moreno-Aspitia A; Colon-Otero G; Pogue-Geile KL; Rasgoti P; Paik S; Perez EA; Thompson EA
    J Natl Compr Canc Netw; 2024 Aug; 22(7):463-468. PubMed ID: 39191270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
    Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
    J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram.
    Jia Z; Xing H; Wang J; Wang X; Wang X; Liu C; He J; Wu S; Miao J; Liu H; Liu Y
    Pathol Res Pract; 2024 Sep; 261():155504. PubMed ID: 39116570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.
    Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH
    Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
    Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
    Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
    J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.